高盛:维持Vaxcyte(PCVX.US)评级,由买入调整至买入评级,目标价由138.00美元调整至100.00美元。Vaxcyte(PCVX.US)公司简介:Vaxcyte Inc是一家疫苗公司,致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者,从而改善全球健康状况。其产品包括肺炎球菌结合疫苗。该公司的候选产品包括VAX-24、VAX-A1和VAX-PG。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.